Agenus (AGEN) Stock Price, News & Analysis

Company Overview

Agenus Inc., a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an antigen 4 (CTLA-4) blocking antibody that is in Phase 2 clinical trial for the treatment of pancreatic cancer and and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in Phase 1 clinical trial; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monospecific antibody; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract that is in a Phase 1 clinical trial; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. The company operates under Agenus, MiNK, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., Incyte Corporation, Merck Sharpe & Dohme, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

Key Stats

• Today's Range: $3.53 to $3.90
• 50-Day Range: $1.51 to $3.84
• 52-Week Range: $1.38 to $19.69
• Volume: 830,616 shs
• Average Volume: 591,903 shs
• Market Capitalization: $97.33 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $9.00
• Consensus Rating: Hold

Agenus Stock Analysis - MarketRank™

Agenus scored higher than 75% of companies evaluated by MarketBeat, and ranked 236th out of 920 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.1 / 5
• Analyst Rating: Hold

Consensus Rating

Agenus has received a consensus rating of Hold. The company's average rating score is 2.17, and is based on 1 buy rating, 5 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Agenus has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Agenus are expected to grow in the coming year, from ($12.55) to ($7.16) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Agenus is -0.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Agenus is -0.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

19.65% of the float of Agenus has been sold short.

Short Interest Ratio / Days to Cover

Agenus has a short interest ratio ("days to cover") of 7.3.

Change versus previous month

Short interest in Agenus has recently decreased by 1.94%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Agenus does not currently pay a dividend.

Dividend Growth

Agenus does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.6 / 5
• Environmental Score: -0.93

Percentage of Shares Shorted

19.65% of the float of Agenus has been sold short.

Short Interest Ratio / Days to Cover

Agenus has a short interest ratio ("days to cover") of 7.3.

Change versus previous month

Short interest in Agenus has recently decreased by 1.94%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.92

News Sentiment

Agenus has a news sentiment score of 0.92. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.03 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Agenus this week, compared to 6 articles on an average week.

Search Interest

14 people have searched for AGEN on MarketBeat in the last 30 days. This is an increase of 27% compared to the previous 30 days.

MarketBeat Follows

8 people have added Agenus to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Agenus insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 5.50% of the stock of Agenus is held by insiders.

Percentage Held by Institutions

61.46% of the stock of Agenus is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

AGEN Stock Analysis - Frequently Asked Questions

How have AGEN shares performed this year?

Agenus' stock was trading at $2.74 at the start of the year. Since then, AGEN stock has increased by 29.6% and is now trading at $3.55.
View the best growth stocks for 2025 here.

How were Agenus' earnings last quarter?

Agenus Inc. (NASDAQ:AGEN) announced its earnings results on Monday, May, 12th. The biotechnology company reported ($1.03) EPS for the quarter, topping the consensus estimate of ($1.61) by $0.58. The biotechnology company had revenue of $24.07 million for the quarter, compared to the consensus estimate of $26.38 million.
Read the conference call transcript.

When did Agenus' stock split?

Agenus shares reverse split before market open on Friday, April 12th 2024. The 1-20 reverse split was announced on Friday, April 12th 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, April 12th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Who are Agenus' major shareholders?

Agenus' top institutional shareholders include Siren L.L.C. (1.82%), AQR Capital Management LLC (2.09%), Goldman Sachs Group Inc. (0.51%) and Charles Schwab Investment Management Inc. (0.30%). Insiders that own company stock include Agenus Inc and Garo H Armen.
View institutional ownership trends.

How do I buy shares of Agenus?

Shares of AGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Agenus own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Agenus investors own include DiamondRock Hospitality (DRH), Waste Connections (WCN), American Water Works (AWK), Voyager Therapeutics (VYGR), The RMR Group (RMR), AUO (AUOTY) and iShares Micro-Cap ETF (IWC).

Company Calendar

• Last Earnings: 5/12/2025
• Today: 5/27/2025
• Next Earnings (Estimated): 8/14/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:AGEN
• CIK: 1098972
• Web: agenusbio.com
• Phone: (781) 674-4400
• Fax: 781-674-4200
• Employees: 440
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $9.00
• High Stock Price Target: $18.00
• Low Stock Price Target: $4.00
• Potential Upside/Downside: +137.8%
• Consensus Rating: Hold
• Rating Score (0-4): 2.17
• Research Coverage: 6 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($8.67)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-245,760,000.00
• Net Margins: -145.89%
• Pretax Margin: -145.89%
• Return on Equity: N/A
• Return on Assets: -85.68%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.19
• Quick Ratio: 0.19

Sales & Book Value

• Annual Sales: $99.52 million
• Price / Sales: 1.04
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($7.78) per share
• Price / Book: -0.49

Miscellaneous

• Outstanding Shares: 27,417,000
• Free Float: 22,380,000
• Market Cap: $103.77 million
• Optionable: Optionable
• Beta: 1.48